$2.27 Billion is the total value of Camber Capital Management LP's 37 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 31.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | Buy | SPDR S&P 500 ETF Trustput | $486,675,000 | +132.3% | 2,250,000 | +125.0% | 21.40% | +111.3% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)adr | $184,040,000 | +27.7% | 4,000,000 | +39.4% | 8.09% | +16.1% |
| MYL | Buy | MYLAN NV | $147,639,000 | +24.6% | 3,873,000 | +41.4% | 6.49% | +13.4% |
| PRGO | Buy | PERRIGO COMPANY | $112,052,000 | +116.8% | 1,213,600 | +112.9% | 4.93% | +97.2% |
| GILD | Buy | GILEAD SCIENCES, INC. | $94,944,000 | +51.8% | 1,200,000 | +60.0% | 4.17% | +38.0% |
| TEVA | Buy | TEVA PHARMACEUTICAL INDUSTRIES LTD (ADR)call | $92,020,000 | +62.8% | 2,000,000 | +77.8% | 4.05% | +48.2% |
| ENDP | Sell | ENDO INT PLC | $85,436,000 | +8.6% | 4,240,000 | -16.0% | 3.76% | -1.2% |
| SEM | Buy | SELECT MEDICAL HOLDINGS CORP | $81,338,000 | +34.2% | 6,025,000 | +8.1% | 3.58% | +22.1% |
| GILD | GILEAD SCIENCES, INC.call | $79,120,000 | -5.2% | 1,000,000 | 0.0% | 3.48% | -13.7% | |
| MDCO | MEDICINES COMPANY | $75,480,000 | +12.2% | 2,000,000 | 0.0% | 3.32% | +2.1% | |
| CSII | Sell | CARDIOVASCULAR SYSTEMS INC | $71,220,000 | -5.5% | 3,000,000 | -26.8% | 3.13% | -14.0% |
| GHDX | GENOMIC HEALTH INC | $71,088,000 | +11.7% | 2,458,100 | 0.0% | 3.12% | +1.6% | |
| BKD | BROOKDALE SENIOR LIVING | $69,800,000 | +13.0% | 4,000,000 | 0.0% | 3.07% | +2.8% | |
| OFIX | ORTHOFIX INTL N V | $64,155,000 | +0.9% | 1,500,000 | 0.0% | 2.82% | -8.3% | |
| LIVN | Sell | LIVANOVA PLC | $60,110,000 | -0.3% | 1,000,000 | -16.7% | 2.64% | -9.3% |
| CYH | Buy | COMMUNITY HEALTH SYS INC NE COM | $57,700,000 | +38.8% | 5,000,000 | +44.9% | 2.54% | +26.3% |
| THC | Buy | TENET HEALTHCARE CORP THC | $56,650,000 | +82.2% | 2,500,000 | +122.2% | 2.49% | +65.7% |
| NKTR | Sell | NEKTAR THERAPEUTICS | $54,976,000 | -9.1% | 3,200,000 | -24.7% | 2.42% | -17.3% |
| UAM | UNIVERSAL AMERICAN CORPORATION | $44,944,000 | +0.9% | 5,875,000 | 0.0% | 1.98% | -8.2% | |
| ALKS | ALKERMES PLC | $44,081,000 | +8.8% | 937,300 | 0.0% | 1.94% | -1.0% | |
| VRX | Sell | VALEANT PHARMACEUTICALS INT (USA) | $31,215,000 | -6.4% | 1,271,500 | -23.2% | 1.37% | -14.9% |
| CNMD | New | CONMED CORP COM | $30,045,000 | – | 750,000 | +100.0% | 1.32% | – |
| BIOS | BIOSCRIP INC | $29,420,000 | +13.3% | 10,180,000 | 0.0% | 1.29% | +3.0% | |
| PTCT | Buy | PTC THERAPEUTICS | $28,020,000 | +166.1% | 2,000,000 | +33.3% | 1.23% | +142.0% |
| NVTA | Sell | INVITAE CORP | $21,393,000 | +5.4% | 2,442,122 | -11.1% | 0.94% | -4.1% |
| ARNA | ARENA PHARMACEUTICALS INC | $18,375,000 | +2.3% | 10,500,000 | 0.0% | 0.81% | -6.9% | |
| ELOS | SYNERON MEDICAL LTD | $16,809,000 | -6.9% | 2,347,593 | 0.0% | 0.74% | -15.3% | |
| AMAG | Buy | AMAG PHARMACEUTICALS | $14,985,000 | +4.4% | 611,390 | +1.9% | 0.66% | -5.0% |
| ELGX | Sell | ENDOLOGIX INC | $12,800,000 | -65.8% | 1,000,000 | -66.7% | 0.56% | -68.8% |
| New | BIOLASE INC | $9,332,000 | – | 5,332,394 | +100.0% | 0.41% | – | |
| PLX | PROTALIX BIO THERAPEUTICS, INC | $7,434,000 | -12.5% | 13,275,000 | 0.0% | 0.33% | -20.4% | |
| INNOCOLL AG | $6,228,000 | +6.7% | 1,059,139 | 0.0% | 0.27% | -2.8% | ||
| CATB | CATABASIS PHARMACEUTICALS INC | $6,160,000 | +66.5% | 1,000,000 | 0.0% | 0.27% | +51.4% | |
| PROTALIX BIO THERAPEUTICS, INCnote 4.500% 9/1 | $5,642,000 | -7.7% | 9,000,000 | 0.0% | 0.25% | -15.9% | ||
| TARGACEPT INCnote | $1,685,000 | 0.0% | 1,684,799 | 0.0% | 0.07% | -8.6% | ||
| DXTRQ | DEXTERA SURGICAL INC. | $1,583,000 | +5.0% | 837,483 | 0.0% | 0.07% | -4.1% | |
| BIOLASE INCcall | $5,000 | +25.0% | 1,841,173 | 0.0% | 0.00% | – | ||
| EPRSQ | Exit | EPIRUS BIOPHARMACEUTICALS | $0 | – | -1,847,500 | -100.0% | -0.04% | – |
| OSUR | Exit | ORASURE TECHNOLOGIES INC | $0 | – | -707,559 | -100.0% | -0.20% | – |
| GNMK | Exit | GENMARK DIAGNOSTICS | $0 | – | -649,097 | -100.0% | -0.27% | – |
| BIOL | Exit | BIOLASE INC | $0 | – | -5,332,394 | -100.0% | -0.30% | – |
| DRRX | Exit | DURECT CORP COM | $0 | – | -6,000,000 | -100.0% | -0.35% | – |
| SQNM | Exit | SEQUENOM INC | $0 | – | -17,325,000 | -100.0% | -0.76% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -4,000,000 | -100.0% | -1.43% | – |
| WMGI | Exit | WRIGHT MEDICAL GROUP NV | $0 | – | -2,475,000 | -100.0% | -2.08% | – |
| NUVA | Exit | NUVASIVE INC. | $0 | – | -750,000 | -100.0% | -2.16% | – |
| ABC | Exit | AMERISOURCEBERGEN CORP | $0 | – | -625,000 | -100.0% | -2.40% | – |
| LDRH | Exit | LDR HOLDING CORP | $0 | – | -1,375,000 | -100.0% | -2.46% | – |
| CI | Exit | CIGNA CORP | $0 | – | -500,000 | -100.0% | -3.09% | – |
| BIIB | Exit | BIOGEN IDEC INC | $0 | – | -275,000 | -100.0% | -3.21% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.